Optimized dendritic cell-based immunotherapy for melanoma: the TriMix-formula

[1]  H. Rammensee,et al.  The regulatory landscape for actively personalized cancer immunotherapies , 2013, Nature Biotechnology.

[2]  B. Neyns,et al.  A phase IB study on intravenous synthetic mRNA electroporated dendritic cell immunotherapy in pretreated advanced melanoma patients. , 2013, Annals of oncology : official journal of the European Society for Medical Oncology.

[3]  L. Zitvogel,et al.  Trial watch , 2013 .

[4]  J. Aerts,et al.  Modulation of Regulatory T Cell Function by Monocyte-Derived Dendritic Cells Matured through Electroporation with mRNA Encoding CD40 Ligand, Constitutively Active TLR4, and CD70 , 2013, The Journal of Immunology.

[5]  C. Heirman,et al.  mRNA: From a chemical blueprint for protein production to an off-the-shelf therapeutic. , 2013, Human vaccines & immunotherapeutics.

[6]  B. Neyns,et al.  Priming of cytotoxic T lymphocyte responses by dendritic cells: induction of potent anti-tumor immune responses , 2013 .

[7]  U. Şahin,et al.  mRNA as a versatile tool for exogenous protein expression. , 2012, Current gene therapy.

[8]  J. Castle,et al.  Targeting the tumor mutanome for personalized vaccination therapy , 2012, Oncoimmunology.

[9]  C. Drake,et al.  Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. , 2012, The New England journal of medicine.

[10]  David C. Smith,et al.  Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. , 2012, The New England journal of medicine.

[11]  C. Mandl,et al.  RNA-based vaccines. , 2012, Vaccine.

[12]  Karolina Palucka,et al.  Cancer immunotherapy via dendritic cells , 2012, Nature Reviews Cancer.

[13]  J. Castle,et al.  Exploiting the mutanome for tumor vaccination. , 2012, Cancer research.

[14]  C. Heirman,et al.  Preclinical evaluation of TriMix and antigen mRNA-based antitumor therapy. , 2012, Cancer research.

[15]  M. Roizen,et al.  Hallmarks of Cancer: The Next Generation , 2012 .

[16]  D. Tyler,et al.  Enhancement of anti‐tumor immunity through local modulation of CTLA‐4 and GITR by dendritic cells , 2011, European journal of immunology.

[17]  Ö. Türeci,et al.  Selective uptake of naked vaccine RNA by dendritic cells is driven by macropinocytosis and abrogated upon DC maturation , 2011, Gene Therapy.

[18]  B. Neyns,et al.  Therapeutic Vaccination With an Autologous mRNA Electroporated Dendritic Cell Vaccine in Patients With Advanced Melanoma , 2011, Journal of immunotherapy.

[19]  Ö. Türeci,et al.  Tumor vaccination using messenger RNA: prospects of a future therapy. , 2011, Current opinion in immunology.

[20]  B. Neyns,et al.  A phase I clinical trial on the combined intravenous (IV) and intradermal (ID) administration of autologous TriMix-DC cellular therapy in patients with pretreated melanoma (TriMixIDIV). , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[21]  M. Debenedette,et al.  Potency of Mature CD40L RNA Electroporated Dendritic Cells Correlates With IL-12 Secretion by Tracking Multifunctional CD8+/CD28+ Cytotoxic T-cell Responses In Vitro , 2011, Journal of immunotherapy.

[22]  Özlem Türeci,et al.  Determinants of intracellular RNA pharmacokinetics: Implications for RNA-based immunotherapeutics , 2011, RNA biology.

[23]  D. Schadendorf,et al.  Improved survival with ipilimumab in patients with metastatic melanoma. , 2010, The New England journal of medicine.

[24]  P. Kantoff,et al.  Sipuleucel-T immunotherapy for castration-resistant prostate cancer. , 2010, The New England journal of medicine.

[25]  S. Held,et al.  RNA Vaccines in Cancer Treatment , 2010, Journal of biomedicine & biotechnology.

[26]  M. Calaminici,et al.  Follicular lymphoma cells induce T-cell immunologic synapse dysfunction that can be repaired with lenalidomide: implications for the tumor microenvironment and immunotherapy. , 2009, Blood.

[27]  J. Gribben,et al.  Peripheral blood T cells in acute myeloid leukemia (AML) patients at diagnosis have abnormal phenotype and genotype and form defective immune synapses with AML blasts. , 2009, Blood.

[28]  B. Neyns,et al.  Single-Step Antigen Loading and Activation of Dendritic Cells by mRNA Electroporation for the Purpose of Therapeutic Vaccination in Melanoma Patients , 2009, Clinical Cancer Research.

[29]  M. Debenedette,et al.  Cytokine Maturation Followed by CD40L mRNA Electroporation Results in a Clinically Relevant Dendritic Cell Product Capable of Inducing a Potent Proinflammatory CTL Response , 2008, Journal of immunotherapy.

[30]  C. Melief.  Cancer immunotherapy by dendritic cells. , 2008, Immunity.

[31]  J. Byrd,et al.  Chronic lymphocytic leukemia T cells show impaired immunological synapse formation that can be reversed with an immunomodulating drug. , 2008, The Journal of clinical investigation.

[32]  B. Neyns,et al.  Enhancing the T-cell stimulatory capacity of human dendritic cells by co-electroporation with CD40L, CD70 and constitutively active TLR4 encoding mRNA. , 2008, Molecular therapy : the journal of the American Society of Gene Therapy.

[33]  M. Lenjou,et al.  Immunosuppression induced by immature dendritic cells is mediated by TGF-β/IL-10 double-positive CD4+ regulatory T cells , 2007, Journal of cellular and molecular medicine.

[34]  J. Villadangos,et al.  Intrinsic and cooperative antigen-presenting functions of dendritic-cell subsets in vivo , 2007, Nature Reviews Immunology.

[35]  H. Rammensee,et al.  Genetic Vaccines and Therapy , 2006 .

[36]  S. Pascolo.  Vaccination with messenger RNA. , 2006, Methods in molecular medicine.

[37]  K. Flaherty,et al.  Clinical activity and immune modulation in cancer patients treated with CP-870,893, a novel CD40 agonist monoclonal antibody. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[38]  A. Enk.  Dendritic cells in tolerance induction. , 2005, Immunology letters.

[39]  J. Borst,et al.  CD27 and CD70 in T cell and B cell activation. , 2005, Current opinion in immunology.

[40]  C. Figdor,et al.  Migration of dendritic cell based cancer vaccines: in vivo veritas? , 2005, Current opinion in immunology.

[41]  J. Kirkwood,et al.  alpha-type-1 polarized dendritic cells: a novel immunization tool with optimized CTL-inducing activity. , 2004, Cancer research.

[42]  S. Pascolo.  Messenger RNA-based vaccines , 2004, Expert opinion on biological therapy.

[43]  E. Gilboa,et al.  Induction of Human Dendritic Cell Maturation Using Transfection with RNA Encoding a Dominant Positive Toll-Like Receptor 41 , 2004, The Journal of Immunology.

[44]  E. Gilboa,et al.  Injection of Immature Dendritic Cells into Adjuvant-Treated Skin Obviates the Need for Ex Vivo Maturation 1 , 2003, The Journal of Immunology.

[45]  C. Figdor,et al.  Maturation of dendritic cells is a prerequisite for inducing immune responses in advanced melanoma patients. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

[46]  V. Engelhard,et al.  Route of Immunization with Peptide-pulsed Dendritic Cells Controls the Distribution of Memory and Effector T Cells in Lymphoid Tissues and Determines the Pattern of Regional Tumor Control , 2003, The Journal of experimental medicine.

[47]  Gerold Schuler,et al.  Immature, semi-mature and fully mature dendritic cells: which signals induce tolerance or immunity? , 2002, Trends in immunology.

[48]  Michel C. Nussenzweig,et al.  Avoiding horror autotoxicus: The importance of dendritic cells in peripheral T cell tolerance , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[49]  A. Enk,et al.  A comparison of two types of dendritic cell as adjuvants for the induction of melanoma‐specific T‐cell responses in humans following intranodal injection , 2001, International journal of cancer.

[50]  Edgar G. Engleman,et al.  Dendritic Cells Injected Via Different Routes Induce Immunity in Cancer Patients1 , 2001, The Journal of Immunology.

[51]  Hua Yu,et al.  Anti-CD40 Antibody Induces Antitumor and Antimetastatic Effects: The Role of NK Cells1 , 2001, The Journal of Immunology.

[52]  F. Sallusto,et al.  Kinetics of dendritic cell activation: impact on priming of TH1, TH2 and nonpolarized T cells , 2000, Nature Immunology.

[53]  R. Crystal,et al.  Dendritic cells modified to express CD40 ligand elicit therapeutic immunity against preexisting murine tumors. , 2000, Blood.

[54]  J. Allison,et al.  Combination Immunotherapy of B16 Melanoma Using Anti–Cytotoxic T Lymphocyte–Associated Antigen 4 (Ctla-4) and Granulocyte/Macrophage Colony-Stimulating Factor (Gm-Csf)-Producing Vaccines Induces Rejection of Subcutaneous and Metastatic Tumors Accompanied by Autoimmune Depigmentation , 1999, The Journal of experimental medicine.

[55]  A. Enk,et al.  Pro‐inflammatory cytokines and prostaglandins induce maturation of potent immunostimulatory dendritic cells under fetal calf serum‐free conditions , 1997, European journal of immunology.